ClinicalTrials.gg
RecruitingNCT05174442Updated Dec 4, 2025

ACCESS Registry: A Post Market Follow-up Study to Monitor the Safety, Performance and Usability of Occlutech Accessory Medical Devices

An observational study in Heart Diseases, sponsored by Occlutech International AB. Recruiting at 36 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Occlutech International AB · Observational

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
685
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Heart Diseases with a site in Turkey — 6 open to participants now, 8 under way, 2 of them phase 3. Heart Diseases · Turkey.

Planned enrollment
Largest of 11
685 · median 239
Started
2021
with 1 other
Observational
11 of 34
2 open now
Registered
12th of 34
by date

Among the 34 studies in Heart Diseases with a site in Turkey, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2021, is one of 11 observational ones, and was the 12th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

6 of the 34 studies in Heart Diseases with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Heart Diseases with a site in Turkey, or all of them as a file.
02

Study summary

The registry is an international, multicenter, non-randomized, non-invasive study to assess the safety, performance and usability of the Occlutech Accessories "Occlutech Delivery Set (ODS), Occlutech Pistol Pusher (OPP), Occlutech Occlusions-Pusher (OOP) and Occlutech Sizing Balloon (OSB)" used for implantation procedures (catheter-based interventions) of cardiac implants via completing surveys (questionnaires) for the accessory medical devices by the investigators.

Read the detailed description

The registry is an international, multicenter, non-randomized, non-invasive study to assess the safety, performance and usability of the Occlutech Accessories "Occlutech Delivery Set (ODS), Occlutech Pistol Pusher (OPP), Occlutech Occlusions-Pusher (OOP) and Occlutech Sizing Balloon (OSB)" used for implantation procedures (catheter-based interventions) of cardiac implants via completing surveys (questionnaires) for the accessory medical devices by the investigators.

A survey (questionnaire) of each accessory medical device should be completed by investigator in order to assess safety of the accessory by success of implantation procedure, occurrence of adverse events during implantation procedure or as late term effects resulting from implantation procedure, user harm related to the accessory, procedure, reported device deficiencies related to the accessory. The Surveys (questionnaires) also include questions related to performance, usability and compatibility with devices and other accessories. Subjects should be treated according to instructions-for-use of the implants and accessories and according to clinical routine. The devices must have been used exclusively by physicians who are experienced in cardiac catheterization techniques and who are experienced in using the products in the process of interventional operations.

03

Conditions studied

  • Heart Diseases

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All subjects who underwent implantation procedure with an Occlutech accessory medical device and cardiac implants can be included. Preconditions depend exclusively on the requirements outlined in the applicable Instruction for Use of the implant and the accessories.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion Criteria depend exclusively on the requirements outlined in the applicable Instruction for Use for accessory medical devices and cardiac implant devices.

All subjects who underwent implantation procedure with an Occlutech accessory medical device and cardiac implants can be included

Exclusion criteria

Exclusion Criteria:

  • Exclusion Criteria depend exclusively on the requirements outlined in the applicable Instruction for Use and if applicable in the corresponding protocol of the investigation on the Occlutech implant devices.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
685 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Occurence of safety events

    The primary safety endpoint is defined as the rate of incidences of (peri-) procedural adverse events / rate of (serious) adverse device effects ((S)ADEs) during implantation or as late effects of implantation procedure. A serious adverse device effect (SADE) is defined as an event that is clearly caused by the device such as: * device dislocation (during the procedures with OPP, OOP,ODS) * embolization related with procedure and accessories * Late effect of implantation procedure: damage to the vessels and heart caused by the accessories * any circumstances that require device removal related with procedure or accessories used during the implantation * Signs of thrombosis

    Time frame: 6 months

Secondary outcomes

  1. Performance, usability:

    will be assessed in terms of mechanical performance, procedural data by completing the survey (questionnaire) for each accessory with grading. Compatibility of ODS, OPP, OOP with cardiac implant devices or/and other accessory medical devices.

    Time frame: 6 months

07

Study locations

28 of 36 sites recruiting
  • Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
    Recruiting
  • Kliniken Maria Hilf GmbH
    Mönchengladbach, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinikum der Universität München
    München, 81377, Germany
    Recruiting
    • Nikolaus Haas, Prof. Dr. med. · Principal investigator
  • Çukurova Üniversitesi Tıp Fakültesi Balcalı Hastanesi
    Adana, Balcalı 01330, Turkey (Türkiye)
    Recruiting
    • Fadli Demir, MD · Contactfadlidemir@yahoo.com
    • Fadli Demir · Principal investigator
    • Nazan Özbarlas · Sub investigator
  • İnönü Üniversitesi Tıp Fakültesi Hastanesi
    Malatya, Battalgazi 44280, Turkey (Türkiye)
    Recruiting
    • · Contact05324666432
    • Özlem Elkiran, Prof. · Principal investigator
  • İzmir Şehir Hastanesi
    Izmir, Bayraklı 35540, Turkey (Türkiye)
    Recruiting
    • Barış Kılıçaslan, MD · Contactkiliaslanbaris@yahoo.com · 0505 588 81 88
    • Barış Kılıçaslan, MD · Principal investigator
  • Aydın Adnan Menderes Üniversitesi Hastanesi
    Aydin, Efeler 09100, Turkey (Türkiye)
    Recruiting
    • Serkan Fazlı Çelik · Contactdocser2003@yahoo.com · 5067795119
    • Serkan Fazlı Çelik · Principal investigator
  • Bezmialem Tıp Fakültesi Hastanesi
    Istanbul, Fatih 34093, Turkey (Türkiye)
    Recruiting
    • Ramazan Ozdemır, Prof. Dr. · Contactrozdemir@bezmialem.edu.tr · 05324636064
    • Ramazan Ozdemır, Prof. Dr. · Principal investigator
  • Antalya Akdeniz Üniversitesi Hastanesi
    Antalya, Konyaaltı 07070, Turkey (Türkiye)
    Withdrawn

    Not enrolling at this site — choose another above.

  • İstanbul Mehmet Akif Ersoy Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi
    Istanbul, Küçükçekmece 34303, Turkey (Türkiye)
    Recruiting
    • Mehmet Ertürk, Prof. · Principal investigator
  • İstanbul Mehmet Akif Ersoy Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi
    Istanbul, Küçükçekmece 34303, Turkey (Türkiye)
    Recruiting
    • Alper Güzeltaş, Prof. · Principal investigator
  • Karaman Eğitim ve Araştırma Hastanesi
    Karaman, Merkez 70200, Turkey (Türkiye)
    Recruiting
    • Ahmet Yılmaz, Dr.Öğr. · ContactDr.ahmetyilmaz@gmail.com · 0090 532 632 91 15
    • Ahmet Yılmaz · Principal investigator
  • Dicle Üniversitesi Tıp Fakültesi Hastanesi
    Diyarbakır, Sur 21280, Turkey (Türkiye)
    Recruiting
  • Medicana International Ankara Hastanesi
    Ankara, Söğütözü 06520, Turkey (Türkiye)
    Not yet recruiting
    • Engin Bozkurt, Prof. · Principal investigator
  • Ankara Etlik Şehir Hastanesi
    Ankara, Yenimahalle 06170, Turkey (Türkiye)
    Recruiting
    • I. Hakan Güllü, MD · Contactdrgullu@gmail.com · 0532 052 14 26
    • I. Hakan Güllü, MD · Principal investigator
  • Adana City Training and Research Hospital
    Adana, Turkey (Türkiye)
    Recruiting
    • İbrahim Halil Kurt, Prof. Dr., MD · Contactibrahimhalilkurt@gmail.com
    • İbrahim Halil Kurt, Prof. Dr., MD · Principal investigator
  • Hacettepe Üniversitesi Hastanesi
    Ankara, 06230, Turkey (Türkiye)
    Recruiting
    • Ergün Barış Kaya, Prof. · Principal investigator
  • Gazi University Medical Faculty Hospital Adult
    Ankara, Turkey (Türkiye)
    Recruiting
    • Salih Topal, MD · Principal investigator
  • Gazi University Medical Faculty Hospital Pediatric
    Ankara, Turkey (Türkiye)
    Recruiting
  • Antalya Training and Research Hospital (Adult)
    Antalya, Turkey (Türkiye)
    Recruiting
    • Şakir Arslan, Prof. · Principal investigator
  • Antalya Training and Research Hospital (Pediatric)
    Antalya, Turkey (Türkiye)
    Recruiting
    • Abdullah Kocabaş, Prof. · Principal investigator
  • SBÜ Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
    Bursa, 16310, Turkey (Türkiye)
    Not yet recruiting
    • Hasan Arı, Prof. · Principal investigator
  • Pamukkale Üniversitesi Klinik Uygulama ve Araştırma Merkezi Hastanesi
    Denizli, 20160, Turkey (Türkiye)
    Recruiting
    • Doğu Akif Kılıç, Prof. · Principal investigator
  • Dicle Üniversitesi Tıp Fakültesi Sağlık ve Araştırma Hastanesi
    Diyarbakır, 21100, Turkey (Türkiye)
    Not yet recruiting
    • Mehmet Ata Akil, Prof. · Principal investigator
  • Eskişehir Osmangazi University Adult
    Eskişehir, Turkey (Türkiye)
    Recruiting
    • Yüksel Çavuşoğlu, MD · Principal investigator
  • Eskişehir Osmangazi University Pediatric
    Eskişehir, Turkey (Türkiye)
    Recruiting
    • Birsen Uçar, MD · Principal investigator
  • Isparta Süleyman Demirel Üniversitesi Araştırma ve Uygulama Hastanesi
    Isparta, 32260, Turkey (Türkiye)
    Recruiting
    • Fathi Akif Aksoy, Prof. · Principal investigator
  • Istanbul Basaksahir Cam and Sakura City Hospital(Adult)
    Istanbul, Turkey (Türkiye)
    Not yet recruiting
    • Alev Kılıçgedik, Prof. Dr., MD · Contactakilicgedik@yahoo.com
    • Alev Kılıçgedik, Prof. Dr., MD · Principal investigator
  • Istanbul Basaksehir Cam and Sakura City Hospital (Pediatric)
    Istanbul, Turkey (Türkiye)
    Recruiting
    • İbrahim Cansaran Tanıdır, Assoc. Prof. Dr., MD · Contact
  • Istanbul Prof. Dr. Suleyman Yalcin City Hospital
    Istanbul, Turkey (Türkiye)
    Not yet recruiting
    • Mustafa Çalışkan, MD, Prof. Dr. · Contactcaliskandr@gmail.com
    • Mustafa Çalışkan, MD, Prof. Dr. · Principal investigator
  • Kocaeli University Hospital
    Kocaeli, Turkey (Türkiye)
    Recruiting
    • Teoman Kılıç, Prof. · Principal investigator
  • Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
    Konya, 142080, Turkey (Türkiye)
    Recruiting
    • Mehmet Akif Düzenli, Prof. · Principal investigator
  • Mardin Artuklu Üniversitesi Tıp Fakültesi Hastanesi
    Mardin, 47200, Turkey (Türkiye)
    Recruiting
    • Mehmet Zülkif Karahan, Prof. · Principal investigator
  • Mersin University Faculty of Medicine Hospital
    Mersin, Turkey (Türkiye)
    Not yet recruiting
    • Derya Karpuz, Assoc. Prof. Dr, MD · Contactdrderyakarpuz@gmail.com
    • Derya Karpuz, Assoc. Prof. Dr., MD · Principal investigator
  • S.B.Ü Ahi Evren Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi
    Trabzon, 61040, Turkey (Türkiye)
    Recruiting
    • Ali Rıza Akyüz, Prof. · Principal investigator
  • Gaziantep Üniversitesi Şahinbey Araştırma ve Uygulama Hastanesi
    Gaziantep, Şehitkamil 27310, Turkey (Türkiye)
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Jan 2027, 62 months after the start.

Of 54 industry-sponsored observational studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 65. This study's planned 62 months is above that.

Counting every sponsor, half of 239 studies reached it within 46 months; a quarter within 18 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Dec 30, 2021
StartActual
Oct 14, 2021
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05174442
Lead sponsor
Occlutech International AB
Responsible party
Sponsor
First posted
Dec 30, 2021
Start date
Oct 14, 2021
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Dec 4, 2025

Study contacts

Gönül Sönmez Utkun
Contact
gonul.sonmezutkun@occlutech.com
+90 542 826 11 95
Inga-Maria Wefel
Contact
dl_occlutech_clinical_team_eu-ist@occlutech.com
+49 171 715 85 88

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion